KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
03 Avril 2024 - 12:30PM
Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of oral, small molecule protease inhibitors,
today announced its management will participate in a fireside chat
at the 23rd Annual Needham Virtual Healthcare Conference on
Wednesday, April 10, 2024 at 10:15 a.m. ET.
A live webcast of the presentation will be available on the
Company’s website at www.kalvista.com. An audio archive will be
available on KalVista’s website for 30 days following the
presentations.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company
focused on the discovery, development, and commercialization of
oral, small molecule protease inhibitors for diseases with
significant unmet need. KalVista disclosed positive phase 3 data
for the KONFIDENT trial for its oral, on-demand therapy
sebetralstat in February 2024. The Company anticipates submitting a
new drug application to the U.S. Food and Drug Administration
(FDA)for sebetralstat in the first half of 2024 and expects to file
for approval in Europe and Japan later in 2024. In addition,
KalVista’s oral Factor XIIa inhibitor program represents a new
generation of therapies that may further improve the treatment for
people living with HAE and other diseases.
For more information about KalVista, please visit
www.kalvista.com.
Forward-Looking Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, timing or
outcomes of communications with the FDA, our expectations about
safety and efficacy of our product candidates, our ability to
obtain regulatory approvals for sebetralstat and other candidates
in development, the success of any efforts to commercialize
sebetralstat, the ability of sebetralstat and other candidates in
development to treat HAE or other diseases, and the future progress
and potential success of our oral Factor XIIa program. Further
information on potential risk factors that could affect our
business and financial results are detailed in our filings with the
Securities and Exchange Commission, including in our annual report
on Form 10-K for the year ended April 30, 2023, our quarterly
reports on Form 10-Q, and our other reports that we may make from
time to time with the Securities and Exchange Commission. We
undertake no obligation to publicly update any forward-looking
statement, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240403658389/en/
KalVista Pharmaceuticals, Inc. Jarrod Aldom Vice
President, Corporate Communications (201) 705-0254
jarrod.aldom@kalvista.com
Ryan Baker Head, Investor Relations (617) 771-5001
ryan.baker@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024